Problems of VirologyProblems of VirologyВопросы вирусологии0507-40882411-2097Central Research Institute for Epidemiology12198ArticlesСтатьиResearch ArticleVirus-Like Particles - A New Strategy for Production of Vaccines against Influenza VirusВирусоподобные частицы - новая стратегия для создания противогриппозных вакцин15042013582VOL 58, NO2 (2013)ТОМ 58, №2 (2013)101409062023Copyright ©; 2013, Petukhova N.V., Ivanov P.A., Migunov A.I.Copyright ©; 2013, Петухова Н.В., Иванов П.А., Мигунов А.И.2013Petukhova N.V., Ivanov P.A., Migunov A.I.Петухова Н.В., Иванов П.А., Мигунов А.И.https://creativecommons.org/licenses/by/4.0https://virusjour.crie.ru/jour/article/view/12198

Numerous studies demonstrated that simultaneous expression of some viral proteins in the cell with the aid of a process of self-assembly might lead to the formation of the virus-like particles (VLP) even in the absence of the viral genome. The morphological and antigenic similarity between VLP and native virions represents a promising approach to the new type of vaccines. In the last decade, the threat of the influenza strains with pandemic potential becomes more important. Therefore, the technology for obtaining a new generation of safe and effective non-embry o culture vaccines was developed on the basis of the influenza VLP produced in various expression systems. This provides great advantages in comparison with existing methods of vaccine production. Such vaccines induced full humoral and cellular immune response in animals and humans. This review is focused on the literature concerning the influenza VLPs obtained in various expression systems including insect, mammalian and plant cells.

Многочисленные исследования показали, что с помощью процесса самосборки одновременная экспрессия некоторых белков вируса гриппа в клетке может приводить к образованию вирусоподобных частиц (ВПЧ) даже в отсутствие вирусного генома. Морфологическое и антигенное сходство гриппозных ВПЧ с нативными вирионами представляет собой перспективную основу для новых противовирусных вакцин. В последнее десятилетие угроза появления штаммов вируса гриппа с пандемической потенцией становится все более актуальной. в связи с этим была разработана технология получения нового поколения безопасных и эффективных неэмбриональных вакцин, полученных на основе гриппозных ВПЧ в различных экспрессионных системах, имеющих значительные преимущества по сравнению с существующими способами производства вакцин. Подобные вакцины индуцируют в организме животных и людей полноценный гуморальный и клеточный иммунный ответ. В настоящем обзоре представлен анализ литературы по теме гриппозных ВПЧ, полученных в различных экспрессионных системах: клетках насекомых, млекопитающих и растений.

influenzavirus-like particlesvaccineexpression systemгриппвирусоподобные частицывакцинаэкспрессионная системаБелжеларская С.Н. Бакуловирусные системы экспрессии рекомбинантных белков в клетках насекомых и млекопитающих. Молекулярная биология. 2011; 1: 142-59.Глик Б., Пастернак Д. Молекулярная биология. Принципы и применение. М.: Мир; 2002.Ali A., Avalos R.T., Ponimaskin E., Nayak D.P. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J. Virol. 2000; 74: 8709-19.Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V. et al. Influenza virus like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007; 25 (19): 3871-78.Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S. et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE. 2008; 3 (1): e1501.Chen B.J., Leser G.P., Morita E., Lamb R.A. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J. Virol. 2007; 81 (13): 7111-23.Cox M.M.J., Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J. of Inverteb. Pathol. 2011; 107: S31-1.Crevar C.J., Ross T.M. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol. J. 2008; 5: 131.D’Aoust M.-A., Lavoie P.O., Couture M.M.-J., Trepanier S., Guay J.M., Dargis M. et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol. J. 2008; 6: 930-40.D’Aoust M.-A., Couture M., Ors F., Trepanier S., Lavoie P.-O., Dargis M., Vezina L.-P. Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin. International Patent application, W02009/076778; 2009.D’Aoust M.-A., Couture M.M., Charland N., Trépanier S., Landry N., Ors F., Vézina L.P. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol. J. 2010; 8: 607-19.Du L., Zhou Y., Jiang S. Research and development of universal influenza vaccines. Microb. Infect. 2010; 12: 280-6.Galarza J.M., Latham T., Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005; 18 (1): 244-51.Giles B.M., Ross T.M. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine. 2011; 29: 3043-54.Gilesа B.M., Bissel S.J., Dealmeida D.R., Wiley C.A., Ross T.M. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin. Vaccine Immunol. 2012; 19 (2): 128-39.Gomez-Puertas P., Albo C., Perez-Pastrana E., Vivo A., Portela A. Influenza virus matrix protein is the major driving force in virus budding. J. Virol. 2000; 74 (24): 11538-47.Guo L., Lu X., Kang S.M., Chen C., Compans R.W., Yao Q. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV viruslike particles. Virology. 2003; 313 (2): 502-13.Hofmann C., Sandig V., Jennings G., Rudolph M., Schlag P., Strauss M. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc. Natl. Acad. Sci. USA. 1995; 92 (22): 10099-103.Holsinger L.J., Lamb R.A. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology. 1991; 183: 32-43.Rossman J. S., Lamb R.A. Influenza virus assembly and budding. Virology, 2011; 411: 229-36.Lai J.C.C., Chan W.W.L., Kien F., Nicholls J.M., Peiris J.S.M., Garcia J.-M. Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase. J. Gen. Virol. 2010; 91: 2322-30.Johansson B.E., Brett I.C. Changing perspective on immunization against influenza. Vaccine. 2007; 25 (16): 3062-65.Kang S.M., Yoo D.G., Lipatov A.S., Song J.M., Davis C.T., Quan F.S. et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS ONE. 2009; 4 (3): e4667.Kang S.M., Song J.-M., Quan F.-S., Compans R.W. Influenza vaccines based on virus-like particles. Virus Res. 2009; 143: 140-46.Khurana S., Wu J., Verma N., Verma S. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of Influenza virus hemagglutinin in humans. J. Virol. 2011; 85 (21): 10945-54.Landry N., Ward B.J., Trépanier S., Montomoli E. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 Influenza. PLoS ONE. 2010; 5: I.12.Lanford R.E., Luckow V., Kennedy R.C., Dreesman G.R., Notvall L., Summers M.D. Expression and characterization of hepatitis B virus surface antigen polypeptides in insect cells with a baculovirus expression system. J. Virol. 1989; 63 (4): 1549-57.Latham T., Galarza J.M. Formation of wild-type and chimeric influenza virus like particles following simultaneous expression of only four structural proteins. J. Virol. 2001; 75 (13): 6154-65.Lerouge P., Cabanes-Macheteau M., Rayon C., Fischette-Laine' A.C., Gomord V, Faye L. N-glycoprotein biosynthesis in plants: recent developments and future trends. Plant Molecular Biol. 1998; 38: 31-48.Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E. et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine. 2008; 26 (42): 5393-99.Marillonnet S., Thoeringer C., Kandzia R., Klimyuk V., Gleba Y. Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nat. Biotechnol. 2005; 23: 718-23.Matassov D., Cupo A., Galarza J.M. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol. 2007; 20 (3): 441-52.Medicago’s avian flu pandemic vaccine achieves 100% protection in a lethal challenge study in ferrets. 2009. URL http://www.medicago.com/English/news/News-Releases/News-ReleaseDetails/2009/MedicagosAvi-anflupandemicvaccineachieves100protectioninalethalchallengestudyinfer-rets1120905/default.aspx [accessed on 27 August 2009].Mena I., Vivo A., Perez E., Portela A. Rescue of a synthetic chloramphenicol acetyltransferase RNA into influenza virus-like particles obtained from recombinant plasmids. J. Virol. 1996; 70: 5016-24.Mett V., Farrance C.E., Green B.J., Yusibov V. Plants as biofactories. Biologicals. 2008; 36: 354-58.Nayak D.P., Balogun R.A., Yamada H., Zhou Z.H., Barman S. Influenza virus morphogenesis and budding. Virus Res. 2009; 143: 147-61.Pan Y.-S., Wei H.-J., Chang C.-C., Lin C.-H., Wei T.-S., Wu S.-C., Chang D.-K. Construction and characterization of insect cell-derived Influenza VLP: cell binding, fusion, and EGFP incorporation. J. Biomed. Biotechnol. 2010; 2010: Article ID 506363. doi:10.1155/2010/506363.Pushko P., Tumpey T.M., Bu F., KnellJ., Robinson R., Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine. 2005; 23 (50): 5751-9.Pushko P., Pearce M.B., Ahmad A., Tretyakova I. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine. 2011; 29 (35): 5911-8.Pushko P., Tumpey T.M., Van Hoeven N., Belser J.A., Robinson R., Nathan, M. et al. Evaluation of influenza virus-like particles and Nova-some adjuvant as candidate vaccine for avian influenza. Vaccine. 2007; 25 (21): 4283-90.Quan F.S., Huang C., Compans R.W., Kang S.M., Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 2007; 81 (7): 3514-24.Quan F.S., Steinhauer D., Huang C., Ross T.M., Compans R.W., Kang S.M. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine. 2008; 26 (26): 3352-61.Quan F.-S., Vunnava A., Compans R.W., Kang S.-M. Virus-like particle vaccine protects against 2009 H1N1 pandemic Influenza virus in mice. PLoS ONE. 2010; 5 (I.2): e9161.Roy P., Noad R. Virus-like particles as a vaccine delivery system. Myths and facts. Hum. Vaccines. 2008; 4 (1): 5-8.Roy B., Liang S., Zhang P., Wang M.-X., Zhou F., David W.C.C., Miao Y. Probability to produce animal vaccines in insect baculovirus expression system. Afr. J. of Biotechnol. 2011; 10 (51): 10323-9.Saint-Jore-Dupas C., Faye L., Gomord V. From planta to pharma with glycosylation in the toolbox. Trends Biotechnol. 2007; 25: 317-23.Sainsbury F., Lomonossoff G.P. Extremely high-level and rapid transient protein production in plants without the use of viral replication. Plant Physiol. 2008; 148: 1212-8.Santi L., Huang Z., Mason H. Virus-like particles production in green plants. Methods. 2006; 40 (1): 66-76.Seveno M., Bardor M., Paccalet T., Gomord V., Lerouge P., Faye L. Glycoprotein sialylation in plants? Nat. Biotechnol. 2004; 22: 1351-52.Song J.-M., Wang B.-Z., Park K.-M., Rooijen N.V., Quan F.-S., Kim M.-C. et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity, PLoS ONE. 2011; 6 (1): e14538.Tang X.-C., Lu H.-R., Ross T.M. Baculovirus-produced Influenza viruslike particles in mammalian cells protect mice from lethal Influenza challenge. Viral Immunol. 2011; 24 (4): 311-9.Vicente T., Roldao A., Peixoto C., Carrondo M.J.T., Alves P.M. Large-scale production and purification of VLP-based vaccines. Journal of Invertebrate Pathology, 2011, V.107, S42-S48.Wang B.-Z., Quan F.-S., Kang S.-M., Bozja J., Skountzou I., Richard W. Incorporation of membrane-anchored flagellin into Influenza virus-like particles enhances the breadth of immune responses. J. Virol. 2008; 82: 11813-23.Wu C.Y., Yeh Y.C., Yang Y.C., Chou C. Mammalian expression of viruslike particles for advanced mimicry of authentic Influenza virus. PLoS ONE. 2010; 5: I.3.Yusibov V., Streatfield S.J., Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals. Vaccines, antibodies and beyond. Hum. Vaccines. 2011; 7 (3): 313-21.